Kanani, Muhammad-KazimNandhra, Harpal2025-04-252025-04-252019-08-13Kanani MK, Nandhra H. Clozapine-induced hepatitis confirmed by rechallenge. Progress in Neurology and Psychiatry 2019; 23(3): 18–20.10.1002/pnp.542http://hdl.handle.net/20.500.14200/7579Clozapine is an atypical antipsychotic that holds a unique role in the management of treatment-resistant schizophrenia. Well known side-effects include agranulocytosis and myocarditis but associated hepatic disorders are less familiar and listed under ‘rare or very rare’ by the British National Formulary.1 However, a transient elevation of transaminases has been estimated to affect up to 50% of patients treated with clozapine.2 This article describes a patient with minimally elevated LFTs who subsequently developed symptomatic hepatitis following the initiation of clozapine therapy.enPharmacologyGastroenterologyMental healthArticle